Skip to content
RDL
Network
Ecosystem
Switch app
TR
About
FAQ
Sign in
Get started
Valsartan reduces the incidence of atrial fibrillation in the patients with heart failure in the Val-HeFT Trial — Aldo Maggioni (2003) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Valsartan reduces the incidence of atrial fibrillation in the patients with heart failure in the Val-HeFT Trial
Shared by
Aldo Maggioni
Valsartan reduces the incidence of atrial fibrillation in the patients with heart failure in the Val-HeFT Trial
Article
2003
en
Authors
Aldo Maggioni
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2005
Valsartan Reduces the Incidence of Atrial Fibrillation in Patients With Heart Failure: Results From the Valsartan Heart Failure Trial (Val-HeFT)
Aldo Maggioni
,
Roberto Latini
,
Peter E. Carson
Article
2005
Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT)
Aldo Maggioni
,
Roberto Latini
,
Peter E. Carson
,
Steven Singh
,
Simona Barlera
,
Robert Glazer
,
Serge Masson
,
E Cerè
,
Gianni Tognoni
,
Jay N. Cohn
Article
2004
Effect of Valsartan Added to Background ACE Inhibitor Therapy in Patients with Heart Failure: Results from Val-HeFT
Henry Krum
,
Peter E. Carson
,
Csaba Farsang
,
Aldo Maggioni
,
Robert Glazer
,
Nora Aknay
,
YannTong Chiang
,
Jay N. Cohn
Article
2010
Elevated Plasma Renin Activity Predicts Adverse Outcome in Chronic Heart Failure, Independently of Pharmacologic Therapy: Data From the Valsartan Heart Failure Trial (Val-HeFT)
Serge Masson
,
Scott D. Solomon
,
Laura Angelici
,
Roberto Latini
,
Inder S. Anand
,
Margaret F. Prescott
,
Aldo Maggioni
,
Gianni Tognoni
,
Jay N. Cohn
Article
2003
1928 The prognostic value of body mass index in patients with heart failure: data from the Val-HeFT trial
Aldo Maggioni
Discussion(0)
No comments yet. Be the first to comment.